S. Tamer

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)

H. Rodbard, M. Piletic, D. Tripathy, 2017, Diabetes, obesity & metabolism.

Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

P. Clauson, K. Rašlová, S. Tamer, 2007, Clinical drug investigation.

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Trine Høyer Rose, S. Seremetis, S. Tamer, 2020 .

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study.

D. Wallace, B. Rojkovich, S. Sierakowski, 2010, Arthritis and rheumatism.

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

P. Clauson, Y. Iwamoto, S. Yoo, 2013, Journal of diabetes investigation.

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

C. Mathieu, E. Franek, D. Russell-Jones, 2013, The Journal of clinical endocrinology and metabolism.